This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sano, C.
Right arrow Articles by Tomioka, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sano, C.
Right arrow Articles by Tomioka, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1999, p. 360-364, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Therapeutic Effects of Benzoxazinorifamycin KRM-1648 Administered Alone or in Combination with a Half-Sized Secretory Leukocyte Protease Inhibitor or the Nonsteroidal Anti-Inflammatory Drug Diclofenac Sodium against Mycobacterium avium Complex Infection in Mice

Chiaki Sano,1,2 Toshiaki Shimizu,1 Katsumasa Sato,1 Hideyuki Kawauchi,2 Shin Kawahara,3 and Haruaki Tomioka1,*

Department of Microbiology and Immunology1 and Department of Otorhinolaryngology,2 Shimane Medical University, Izumo, Shimane 693-8501, Japan, and Department of Internal Medicine, National Sanatorium, Minami-Okayama Hospital,3 Okayama 701-0304, Japan

Received 15 May 1998/Returned for modification 11 August 1998/Accepted 6 November 1998

The effects of half-sized secretory leukocyte protease inhibitor or diclofenac sodium administered alone or in combination with the benzoxazinorifamycin KRM-1648 on the therapeutic efficacy of KRM-1648 against Mycobacterium avium complex (MAC) in mice were studied. Neither of the two anti-inflammatory drugs affected the efficacy of KRM-1648, while they exerted significant modulating effects on tumor necrosis factor alpha production by MAC-infected macrophages.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Shimane Medical University, Izumo, Shimane 693-8501, Japan. Phone: 81 (853) 20-2146. Fax: 81 (853) 20-2145. E-mail: tomioka{at}shimane-med.ac.jp.

Antimicrobial Agents and Chemotherapy, February 1999, p. 360-364, Vol. 43, No. 2
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.




Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»